Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy
Not Applicable
- Conditions
- Hymenoptera Venom Allergy
- Interventions
- Biological: Hymenoptera venom
- Registration Number
- NCT00947908
- Lead Sponsor
- University of Rostock
- Brief Summary
Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Patients with diagnosed hymenoptera venom allergy
- No previous treatments for hymenoptera venom allergy
Exclusion Criteria
- Treatment with immunosuppressive agents
- Any malignant disease
- Infections within 1 week prior to the initiation of the treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A Hymenoptera venom Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
- Primary Outcome Measures
Name Time Method Number of myeloid DC and plasmacytoid DC in peripheral blood Directly before, 1 hour after, and 12 months after initiation of immune therapy
- Secondary Outcome Measures
Name Time Method Surface molecule expression on myeloid DC and plasmacytoid DC Directly before, 1 hour after, and 12 months after initiation of immune therapy
Trial Locations
- Locations (1)
University of Rostock
🇩🇪Rostock, mecklenburg-Vorpommern, Germany